Trends in Death Rates Among U.S. Adults With and Without Diabetes Between 1997 and 2006

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Diabetes care (Impact Factor: 8.57). 06/2012; 35(6):1252-7. DOI: 10.2337/dc11-1162
Source: PubMed

ABSTRACT To determine whether all-cause and cardiovascular disease (CVD) death rates declined between 1997 and 2006, a period of continued advances in treatment approaches and risk factor control, among U.S. adults with and without diabetes.
We compared 3-year death rates of four consecutive nationally representative samples (1997-1998, 1999-2000, 2001-2002, and 2003-2004) of U.S. adults aged 18 years and older using data from the National Health Interview Surveys linked to National Death Index.
Among diabetic adults, the CVD death rate declined by 40% (95% CI 23-54) and all-cause mortality declined by 23% (10-35) between the earliest and latest samples. There was no difference in the rates of decline in mortality between diabetic men and women. The excess CVD mortality rate associated with diabetes (i.e., compared with nondiabetic adults) decreased by 60% (from 5.8 to 2.3 CVD deaths per 1,000) while the excess all-cause mortality rate declined by 44% (from 10.8 to 6.1 deaths per 1,000).
Death rates among both U.S. men and women with diabetes declined substantially between 1997 and 2006, reducing the absolute difference between adults with and without diabetes. These encouraging findings, however, suggest that diabetes prevalence is likely to rise in the future if diabetes incidence is not curtailed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study analyzed the lifetime healthcare expenditures and life years lost associated with diabetes in the U.S. Data from the National Health Interview Survey (NHIS), the Medical Expenditure Panel Survey from 1997 to 2000, and the NHIS Linked Mortality Public-use Files with a mortality follow-up to 2006 were used to estimate age-, race-, sex-, and BMI-specific risk of diabetes, mortality, and annual healthcare expenditures for both patients with diabetes and nondiabetics. A Markov model populated by the risk and cost estimates was used to compute life years and total lifetime healthcare expenditures by age, race, sex, and BMI classifications for patients with diabetes and without diabetes. Predicted life expectancy for patients with diabetes and without diabetes demonstrated an inverted U shape across most BMI classifications, with highest life expectancy being for the overweight. Lifetime healthcare expenditures were higher for whites than blacks and for females than males. Using U.S. adults aged 50 years as an example, we found that diabetic white females with a BMI >40 kg/m(2) had 17.9 remaining life years and lifetime health expenditures of $185,609, whereas diabetic white females with normal weight had 22.2 remaining life years and lifetime health expenditures of $183,704. Our results show that obesity is associated with large decreases in life expectancy and large increases in lifetime healthcare expenditures. In addition to decreasing life expectancy by 3.3 to 18.7 years, diabetes increased lifetime healthcare expenditures by $8,946 to $159,380 depending on age-race-sex-BMI classification groups. © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
    Diabetes Care 12/2014; 38(3). DOI:10.2337/dc14-1453 · 8.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to investigate trends in the estimated 10-year risk for developing cardiovascular disease (CVD) among adults with diagnosed diabetes in Oman. In addition, the effect of hypothetical risk reductions in this population was examined. Data from 1,077 Omani adults aged ≥40 years with diagnosed diabetes were collected and analysed from three national surveys conducted in 1991, 2000 and 2008 across all regions of Oman. The estimated 10-year CVD risk and hypothetical risk reductions were calculated using risk prediction algorithms from the Systematic COronary Risk Evaluation (SCORE), Diabetes Epidemiology Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) and World Health Organization/International Society of Hypertension (WHO/ISH) risk tools. Between 1991 and 2008, the estimated 10-year risk of CVD increased significantly in the total sample and among both genders, regardless of the risk prediction algorithm that was used. Hypothetical risk reduction models for three scenarios (eliminating smoking, controlling systolic blood pressure and reducing total cholesterol) identified that reducing systolic blood pressure to ≤130 mmHg would lead to the largest reduction in the 10-year risk of CVD in subjects with diabetes. The estimated 10-year risk for CVD among adults with diabetes increased significantly between 1991 and 2008 in Oman. Focused public health initiatives, involving recognised interventions to address behavioural and biological risks, should be a national priority. Improvements in the quality of care for diabetic patients, both at the individual and the healthcare system level, are required.
    Sultan Qaboos University medical journal 02/2015; 15(1):e39-45.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiometabolic risk (CMR) refers to the collective consideration of traditional and emerging risk factors that amplify the potential of developing atherogenic cardiovascular disease, as well as the emergence of type 2 diabetes mellitus. Cumulative data suggest that the metabolic syndrome confers a 5-fold increase in risk for type 2 diabetes mellitus and also increases the cardiovascular risk calculated by conventional algorithms by an additional 1.5- to 2.0-fold. This article is a summary of the recently published position article on cardiometabolic risk by the nationally represented inter-disciplinary Cardiometabolic Risk Working Group (Can J Cardiol. 2011;27:e1–e33). The objective of this article is to review what the emerging risk factors are, how to determine if individuals at risk for or with type 2 diabetes mellitus have elevated CMR and the steps that should be taken to optimally manage and reduce CMR in these patients.
    Canadian Journal of Diabetes 12/2012; 36(6):320-326. DOI:10.1016/j.jcjd.2012.08.009 · 0.46 Impact Factor

Preview (2 Sources)

1 Download
Available from